RAP-103 in Tg4510 Mouse Model of Alzheimer's Disease: PET and Histology Data

This dataset supports the NIH Final Research Performance Progress Report (FRPPR) for grant 5R43AG085779, titled "CCR5 Antagonist Therapy to Protect Synapses and Reduce Neuroinflammation in Alzheimer’s Disease". It contains imaging and histological data from the Tg4510 mouse model, including:- PET imaging with SV2A tracer (Yale University)- Immunohistochemistry for pTau231, IBA1, GFAP, and NeuN (Psychogenics, Inc.)- Final FRPPR report with embedded figures- Raw data, figure images, methods summary, and structured documentation These results describe the effects of the CCR5 antagonist RAP-103 on synaptic markers, glial activation, and tau phosphorylation. Data were collected under IACUC-approved protocols. Group sizes: n = 5–6 per condition. Please cite this dataset using the Zenodo DOI and reference NIH Grant 5R43AG085779 in any derivative publications. AUTHORS:- Michael Ruff, Creative Bio-Peptides, Inc. - Takashi Toyonaga, Yale University - Carla Smith, Psychogenics Inc.本数据集可支持编号为5R43AG085779的资助项目对应的美国国立卫生研究院（National Institutes of Health, NIH）最终研究执行进度报告（Final Research Performance Progress Report, FRPPR），项目标题为《CCR5拮抗剂疗法用于保护阿尔茨海默病患者的突触并减轻神经炎症》。 本数据集包含来自Tg4510小鼠模型的影像学与组织学数据，具体涵盖以下内容： - 采用SV2A示踪剂的正电子发射断层扫描（Positron Emission Tomography, PET）成像（耶鲁大学提供） - 针对pTau231、IBA1、GFAP及NeuN的免疫组织化学检测（Psychogenics, Inc.完成） - 内嵌图表的最终FRPPR报告 - 原始数据、图表图像、方法概述及结构化文档 本数据集的结果阐释了CCR5拮抗剂RAP-103对突触标志物、神经胶质激活及tau蛋白磷酸化的影响。所有数据均按照经国际动物护理和使用委员会（Institutional Animal Care and Use Committee, IACUC）批准的实验方案采集，各组样本量为每组n=5~6。 若基于本数据集开展衍生研究并发表成果，请引用Zenodo平台的数字对象标识符（Digital Object Identifier, DOI），并标注美国国立卫生研究院资助项目编号5R43AG085779。 作者列表： - Michael Ruff，Creative Bio-Peptides, Inc. - Takashi Toyonaga，耶鲁大学 - Carla Smith，Psychogenics Inc.